AI Platform for Structure-Guided Molecular Discovery
Design nanobodies, mini-binders and small molecules using structural biology and AI.
Design nanobodies, mini-binders and small molecules using structural biology and AI.
CycloGen AI integrates protein structure prediction, molecular docking, binder engineering and ligand design into a unified discovery platform.
Researchers can explore molecular space, predict protein structures and design therapeutic molecules using advanced AI models — all without writing a single line of code.
Comprehensive AI-powered tools for every stage of therapeutic discovery
Engineer compact single-domain antibodies with enhanced stability and unique binding capabilities.
Engineer compact, high-affinity binders for diagnostic and therapeutic applications.
Predict protein structures with state-of-the-art deep learning models.
Identify and validate novel therapeutic targets through AI-powered analysis.
Analyze mutation impact on protein function, stability and drug resistance.
Discover and optimize small molecule ligands using AI-driven docking and scoring.
CycloGen AI accelerates the discovery pipeline from target identification to candidate molecule design.
The platform combines deep learning, structural biology and computational chemistry to enable faster molecular discovery with higher success rates.
Integrated tools powering next-generation molecular discovery
Join leading biotech companies accelerating their drug discovery pipeline
Or contact us directly at sales@cyclogen.ai
Hospitals, research institutes, and biotech startups without dedicated AI/ML teams are now co-developing therapeutics with CycloGen AI — accelerating discovery programs that would otherwise take years of internal investment.
Start Co-Development